Jeff Mirviss

@bsc_pi

Global President, PI, @bsc_vascular & @bsc_io at BSC. Passionate about the role of med tech in saving the lives and limbs of patients around the world.

Maple Grove, MN

Joined August 2009

2KFollowing

2KFollowers

Jeff Mirviss@bsc_pi · Jul 25

Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium & @UnimedizinMainz. Learn more: bit.ly/44VQapx

bsc_pi's tweet image. Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium &amp; @UnimedizinMainz. Learn more: bit.ly/44VQapx

10.0K

Jeff Mirviss@bsc_pi · Jul 8

FDA-approved. Clinically proven. Minimally invasive. #RangerDCB brings next-gen performance to #PAD procedures. Explore the new 200cm monorail platform: bit.ly/46vrMxa #DCB

265

Jeff Mirviss@bsc_pi · Jun 9

Introducing #ENROUTE: The first and only transcarotid artery revascularization (#TCAR) system that reverses blood flow during stenting to protect the brain. See why physicians are making the switch: bit.ly/44616RY #OnePowerfulSwitch *Available in US only

940

Jeff Mirviss Retweeted

Cat Jennings@bsc_vascular · May 27

🗓️ Join us at #NCVH2025 for a live case featuring an expert operator and panel who will discuss the application of #Ranger200cm to treat complex lesions and evidence-based decision making with #drugeluting therapies. #DCB #DrugCoatedBalloon #PAD

481

Jeff Mirviss@bsc_pi · Apr 22

Excited to share that our dedicated investigators, @PERTConsortium & @UnimedizinMainz, have enrolled the 500th patient in #HIPEITHO! HI-PEITHO is the seminal global prospective multicenter RCT with primary endpoints that will be meaningful to all who manage patients with #PE

bsc_pi's tweet image. Excited to share that our dedicated investigators, @PERTConsortium &amp; @UnimedizinMainz, have enrolled the 500th patient in #HIPEITHO! HI-PEITHO is the seminal global prospective multicenter RCT with primary endpoints that will be meaningful to all who manage patients with #PE

5.0K

Jeff Mirviss Retweeted

Cat Jennings@bsc_vascular · Apr 22

Join us for an enlightening discussion as thought leaders spanning diverse medical specialties share the latest clinical data & their perspectives on the future of #PE. @PERTConsortium @drksterling @DKadiandodov @monteleoneMD #MedEd Register now: bit.ly/42Uy0o7

157

Jeff Mirviss@bsc_pi · Apr 2

Exciting news! Boston Scientific has officially closed the acquisition of @BoltIVL. We look forward to enhancing our PI portfolio and providing physicians and their patients with this advanced, innovative therapy for complex vascular diseases. #BoltIVL #ATK #BTK

BBoston Scientific@bostonsci · Apr 2

We have officially closed the acquisition of @BoltIVL. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease. $BSX

703

Jeff Mirviss Retweeted

Vascular News@VascularNews · Jan 29

New data from a large, real-world study support the use of drug-eluting devices to reduce amputations, readmissions, and healthcare costs in the treatment of #PAD, Marianne Brodmann informed attendees at #LINC2025 vascularnews.com/drug-eluting-t…

816

Jeff Mirviss@bsc_pi · Jan 29

Presented at #LINC2025 | Ranger ISR analysis from the #ELEGANCERegistry showed high 84.2% K-M rate of freedom from CD-TLR rate at 12m across this diverse and complex 150-patient population, which included nearly 50% females and over 30% under-represented minorities. #RangerISR

bsc_pi's tweet image. Presented at #LINC2025 | Ranger ISR analysis from the #ELEGANCERegistry showed high 84.2% K-M rate of freedom from CD-TLR rate at 12m across this diverse and complex 150-patient population, which included nearly 50% females and over 30% under-represented minorities. #RangerISR

540

Jeff Mirviss@bsc_pi · Jan 28

Presented at #LINC2025 | TRUE-PTX data show that #PAD treatment with #paclitaxel #drugeluting devices may reduce the risk of amputation and readmission vs. treatment with non-drug devices. #TRUEPTX #EvidenceBasedMedicine

bsc_pi's tweet image. Presented at #LINC2025 | TRUE-PTX data show that #PAD treatment with #paclitaxel #drugeluting devices may reduce the risk of amputation and readmission vs. treatment with non-drug devices. #TRUEPTX #EvidenceBasedMedicine

637

Jeff Mirviss@bsc_pi · Jan 8

Big news! Upon close and regulatory approval, we look forward to providing physicians and their patients access to this emerging, high-growth therapy for treatment of complex cardiovascular diseases.

BBoston Scientific@bostonsci · Jan 8

We’ve agreed to acquire @BoltIVL, developer of an intravascular lithotripsy (IVL) offering to treat coronary and peripheral disease, which will expand our cardiovascular portfolio with a complementary & differentiated calcium modification platform. bit.ly/3DXLmG3 $BSX

2.0K

Jeff Mirviss Retweeted

Silk Road Medical@SilkRoadMed · Nov 27

Continue following Silk Road Medical’s journey, now as a part of #BostonScientific, by following @bsc_pi and @bsc_vascular. #ForwardTogether #ENROUTE

785

Jeff Mirviss@bsc_pi · Nov 19

We’re excited to add TCAR technology to Boston Scientific’s portfolio. CAD is a rapidly growing therapy area affecting nearly half a million new patients annually in the US. As one company, we’re excited to bring this therapy to more patients. *Available only in US currently

653

Jeff Mirviss Retweeted

Cat Jennings@bsc_vascular · Nov 8

🗓️Join us next week to discuss The "Usual" Intermediate-High Risk PE Case…And "What Else” - The Usual: Standard PE case - What Else: Case with PFO present - What Else: Case with very short duration, low dose lytic protocol Register Today: qrco.de/ViEWebinar

219

Jeff Mirviss Retweeted

Silk Road Medical@SilkRoadMed · Nov 5

ROADSTER 3 30-day outcomes are in: TCAR delivers the lowest stroke rates in the first-ever independently adjudicated study for standard surgical risk patients. Learn More about the ROADSTER 3 Clinical Data: silkroadmed.com/healthcare-pro… Learn More about TCAR: silkroadmed.com/healthcare-pro…

474

Jeff Mirviss Retweeted

Cat Jennings@bsc_vascular · Oct 30

Headed to #TheVEINS24 and #VIVA24? Don't miss these Boston Scientific events! 🗓️ @TheVEINSatVIVA @VIVAPhysicians @bsc_pi

1.0K

Jeff Mirviss@bsc_pi · Oct 28

Presented at #TCT2024 | Novel #ELEGANCE Patient Preference Information (PPI) will help clinicians understand the experience of diverse patients & deliver more patient-centric, precision care by race, ethnicity & sex. #EvidenceBasedMedicine #healthequity #clinicaltrialdiversity

bsc_pi's tweet image. Presented at #TCT2024 | Novel #ELEGANCE Patient Preference Information (PPI) will help clinicians understand the experience of diverse patients &amp; deliver more patient-centric, precision care by race, ethnicity &amp; sex. #EvidenceBasedMedicine #healthequity #clinicaltrialdiversity

438

Jeff Mirviss Retweeted

Cardiovascular Research Foundation@crfheart · Oct 28

🚨 #TCT2024 White Sneaker Day is tomorrow! 🏃‍♂️✨ Rally your colleagues, lace up your white sneakers, & snap the ultimate group selfie! 📸👟 Tag your photos with #TCTWhiteSneakerDay! 👉 ow.ly/hWuO50TT143 @djc795 @jgranadacrf @Drroxmehran @sahilparikhmd @triciarawh

3.0K